We are live on ! Find out more
ENZN

ENZON PHARMACEUTICALS INC
ENZN

Delisted

ENZN was delisted on the 19th of May, 2016.

57 hedge funds and large institutions have $21.1M invested in ENZON PHARMACEUTICALS INC in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less funds holding

Funds holding: 6557 (-8)

14% less capital invested

Capital invested by funds: $24.6M → $21.1M (-$3.5M)

45% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 22

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
57
Holders Change
-8
Holders Change %
-12.31%
% of All Funds
1.52%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
12
Reduced
22
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
IC
1
Icahn Carl
Florida
$6.44M
BIT
2
BlackRock Institutional Trust
California
$3.31M -$27.6K -26,252 -0.9%
Renaissance Technologies
3
Renaissance Technologies
New York
$1.97M +$245K +233,300 +15%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.41M +$13.4K +12,736 +1%
BIP
5
Brandes Investment Partners
California
$1.13M -$3.05K -2,910 -0.3%
BA
6
BlackRock Advisors
Delaware
$865K
CSC
7
Cove Street Capital
California
$777K
UBS Group
8
UBS Group
Switzerland
$771K +$743K +707,951 New
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$470K +$119K +113,400 +32%
Invesco
10
Invesco
Georgia
$343K +$16.9K +16,095 +5%
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$319K +$59K +56,200 +24%
Connor, Clark & Lunn Investment Management (CC&L)
12
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$251K +$9.76K +9,300 +4%
NFA
13
Nationwide Fund Advisors
Ohio
$242K -$62.3K -59,343 -21%
Goldman Sachs
14
Goldman Sachs
New York
$237K -$163K -155,274 -42%
SIM
15
Spark Investment Management
New York
$228K -$44K -41,900 -16%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$199K
Millennium Management
17
Millennium Management
New York
$198K +$8.96K +8,538 +5%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$180K -$17.8K -17,000 -9%
CL
19
CSS LLC
Illinois
$173K -$40.2K -38,350 -19%
AG
20
Algert Global
California
$136K
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$133K
Two Sigma Investments
22
Two Sigma Investments
New York
$130K -$41.2K -39,215 -25%
BIM
23
Bogle Investment Management
Massachusetts
$129K -$10.4K -9,919 -8%
Morgan Stanley
24
Morgan Stanley
New York
$128K -$75K -71,465 -38%
Arrowstreet Capital
25
Arrowstreet Capital
Massachusetts
$126K

ENZN Hedge Fund Activity: Q4 2014 in Review

57 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q4 2014, worth a combined $21.1M — down 14% from $24.6M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ENZN and 5 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 12 added.

The largest buyer was Renaissance Technologies, adding an estimated $245K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $1.19M sold.

  • 57 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q4 2014, down from 65 in Q3 2014.
  • Funds reported $21.1M of ENZON PHARMACEUTICALS INC stock for Q4 2014, down 14% quarter-over-quarter.
  • 5 funds opened new ENZON PHARMACEUTICALS INC positions in Q4 2014 and 12 closed out, a net change of -7 holders.
  • The largest ENZON PHARMACEUTICALS INC buyer in Q4 2014 was Renaissance Technologies, an estimated $245K added.
  • The largest ENZON PHARMACEUTICALS INC seller in Q4 2014 was Dimensional Fund Advisors, an estimated $1.19M sold.

Based on aggregated 13F filings for Q4 2014.